BasiccvandcvClinicalcvPharmacologycv14thcvEditioncvKatzungcvTrevorcvTestcvBank
FULLcvTESTBANK
RRRRRRINSTANTcvDOWNLOAD!!
,BasiccvandcvClinicalcvPharmacologycv14thcvEditioncvKatzungcvTrevorcvTestc v Ba
nk
Chaptercv1.cvIntroduction:cvThecvNaturecvofcvDrugscv&cvDrugcvDevelopmentcv&cvRegulation
1.
Acvnursecvworkingcvincvradiologycvadministerscviodinecvtocvacvpatientcvwhocv
iscvhavingcvacvcomputedcvtomographycv(CT)cvscan.cvThecvnursecvworkingcvoncv
thecvoncologycvunitcvadministerscvchemotherapycvtocvpatientscvwhocvhavecvcan
cer.cvAtcvthecvPubliccvHealthcvDepartment,cvacvnursecvadministerscvacvmeasles-
mumps-rubellacv(MMR)cvvaccinecvtocvacv14-month-
oldcvchildcvascvacvroutinecvimmunization.cvWhichcvbranchcvofcvpharmacologycv
bestcvdescribescvthecvactionscvofcvallcvthreec v nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacologycviscvthecvstudycvofcvthecvbiologiccveffectscvofcvchemicals.cvNurs
escvarecvinvolvedcvwithcvclinicalcvpharmacologycvorcvpharmacotherapeutics,cv
whichcviscvacvbranchcvofcvpharmacologycvthatcvdealscvwithcvthecvusescvofcvdrug
scvtocvtreat,cvprevent,cvandcvdiagnosecvdisease.cvThecvradiologycvnursecviscvadm
inisteringcvacvdrugcvtocvhelpcvdiagnosecvacvdisease.cvThecvoncologycvnursecviscva
dministeringcvacvdrugcvtocvhelpcvtreatcvacvdisease.cvPharmacoeconomicscvinclud
escvanycvcostscvinvolvedcvincvdrugcvtherapy.
Pharmacodynamicscvinvolvescvhowcvacvdrugcvaffectscvthecvbodycvandcvpharmac
okineticscviscvhowcvthecvbodycvactscvoncvthecvbody.
,2.
Acvphysiciancvhascvorderedcvintramuscularcv(IM)cvinjectionscvofcvmorphine,
a narcotic,cveverycv4cvhourscvascvneededcvforcvpaincvincvacvmotorcvvehiclecvac
cv cv
cidentcvvictim.cvThecvnursecviscvawarecvthiscvdrugcvhascvacvhighcvabusecvpotenti
al.cvUndercvwhatcvcategorycvwouldcvmorphinecvbecvclassified?
A) SchedulecvI
B) SchedulecvII
C) SchedulecvIII
D) SchedulecvIV
Ans: B
Feedback:
NarcoticscvwithcvacvhighcvabusecvpotentialcvarecvclassifiedcvascvSchedulecvIIcv
drugscvbecausecvofcvseverecvdependencecvliability.cvSchedulecvIcvdrugscvhavec
vhighcvabusecvpotentialcvandcvnocvacceptedcvmedicalcvuse.cvSchedulecvIIIcvdru
gscvhavecvacvlessercvabusecvpotentialcvthancvIIcvandcvancvacceptedcvmedicalcvus
e.cvSchedulecvIVcvdrugscvhavecvlowcvabusecvpotentialcvandcvlimitedcvdependen
cecvliability.
3.
WhencvinvolvedcvincvphasecvIIIcvdrugcvevaluationcvstudies,cvwhatcvrespon
sibilitiescvwouldcvthecvnursecvhave?
A) Workingcvwithcvanimalscvwhocvarecvgivencvexperimentalc v drugs
B) Choosingcvappropriatecvpatientscvtocvbecvinvolvedcvincvthecvdrugc v study
C) Monitoringcvandcvobservingcvpatientscvcloselycvforcvadversec v effects
D) Conductingcvresearchcvtocvdeterminecveffectivenesscvofcvthec v drug
Ans: C
Feedback:
, PhasecvIIIcvstudiescvinvolvecvusecvofcvacvdrugcvincvacvvastcvclinicalcvpopulationcv
incvwhichcvpatientscvarecvaskedcvtocvrecordcvanycvsymptomscvtheycvexperiencec
vwhilecvtakingcvthecvdrugs.cvNursescvmaycvbecvresponsiblecvforcvhelpingcvcolle
ctcvandcvanalyzecvthecvinformationcvtocvbecvsharedcvwithcvthecvFoodcvandcvDrugc
vAdministrationcv(FDA)cvbutcvwouldcvnotcvconductcvresearchcvindependentlycv
becausecvnursescvdocvnotcvprescribecvmedications.cvUsecvofcvanimalscvincvdrugc
vtestingcviscvdonecvincvthecvpreclinicalcvtrials.cvSelectcvpatientscvwhocvarecvinvo
lvedcvincvphasecvIIcvstudiescvtocvparticipatecvincvstudiescvwherecvthecvparticipan
tscvhavecvthecvdiseasecvthecvdrugcviscvintendedcvtocvtreat.cvThesecvpatientscvarecv
monitoredcvcloselycvforcvdrugcvactioncvandcvadversecveffects.cvPhasecvIcvstudie
scvinvolvecvhealthycvhumancvvolunteerscvwhocvarecvusuallycvpaidcvforcvtheircvp
articipation.cvNursescvmaycvobservecvforcvadversecveffectscvandcvtoxicity.
4.
Whatcvconceptcviscvconsideredcvwhencvgenericcvdrugscvarecvsubstitutedcv
forcvbrandcvnamecvdrugs?
A) Bioavailability
B) Criticalcvconcentration
C) Distribution
D) Half-life
Ans: A
Feedback:
Bioavailabilitycviscvthecvportioncvofcvacvdosecvofcvacvdrugcvthatcvreachescvthecvs
ystemiccvcirculationcvandcviscvavailablecvtocvactcvoncvbodycvcells.cvBinderscvus
edcvincvacvgenericcvdrugcvmaycvnotcvbecvthecvsamecvascvthosecvusedcvincvthecvbr
andcvnamecvdrug.cvTherefore,cvthecvwaycvthecvbodycvbreakscvdowncvandcvusesc
vthecvdrugcvmaycvdiffer,cvwhichcvmaycveliminatecvacvgenericcvdrugcvsubstitutio
n.cvCriticalcvconcentrationcviscvthecvamountcvofcvacvdrugcvthatcviscvneededcvtocv
causecvacvtherapeuticcveffectcvandcvshouldcvnotcvdiffercvbetweencvgenericcvand
cvbrandcvnamecvmedications.cvDistributioncviscvthecvphasecvofcvpharmacokinet
ics,cvwhichcvinvolvescvthecvmovementcvofcvacvdrugcvtocvthecvbodyscvtissuescva
ndcviscvthecvsamecvincvgenericcvandcvbrandcvnamecvdrugs.cvAcvdrugscvhalf-
lifecviscvthecvtimecvitcvtakescvforcvthecvamountcvofcvdrugcvtocvdecreasecvtocvhalfc
vthecvpeakcvlevel,cvwhichcvshouldcvnotcvchangecvwhencvsubstitutingcvacvgeneri
cc v medication.
FULLcvTESTBANK
RRRRRRINSTANTcvDOWNLOAD!!
,BasiccvandcvClinicalcvPharmacologycv14thcvEditioncvKatzungcvTrevorcvTestc v Ba
nk
Chaptercv1.cvIntroduction:cvThecvNaturecvofcvDrugscv&cvDrugcvDevelopmentcv&cvRegulation
1.
Acvnursecvworkingcvincvradiologycvadministerscviodinecvtocvacvpatientcvwhocv
iscvhavingcvacvcomputedcvtomographycv(CT)cvscan.cvThecvnursecvworkingcvoncv
thecvoncologycvunitcvadministerscvchemotherapycvtocvpatientscvwhocvhavecvcan
cer.cvAtcvthecvPubliccvHealthcvDepartment,cvacvnursecvadministerscvacvmeasles-
mumps-rubellacv(MMR)cvvaccinecvtocvacv14-month-
oldcvchildcvascvacvroutinecvimmunization.cvWhichcvbranchcvofcvpharmacologycv
bestcvdescribescvthecvactionscvofcvallcvthreec v nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacologycviscvthecvstudycvofcvthecvbiologiccveffectscvofcvchemicals.cvNurs
escvarecvinvolvedcvwithcvclinicalcvpharmacologycvorcvpharmacotherapeutics,cv
whichcviscvacvbranchcvofcvpharmacologycvthatcvdealscvwithcvthecvusescvofcvdrug
scvtocvtreat,cvprevent,cvandcvdiagnosecvdisease.cvThecvradiologycvnursecviscvadm
inisteringcvacvdrugcvtocvhelpcvdiagnosecvacvdisease.cvThecvoncologycvnursecviscva
dministeringcvacvdrugcvtocvhelpcvtreatcvacvdisease.cvPharmacoeconomicscvinclud
escvanycvcostscvinvolvedcvincvdrugcvtherapy.
Pharmacodynamicscvinvolvescvhowcvacvdrugcvaffectscvthecvbodycvandcvpharmac
okineticscviscvhowcvthecvbodycvactscvoncvthecvbody.
,2.
Acvphysiciancvhascvorderedcvintramuscularcv(IM)cvinjectionscvofcvmorphine,
a narcotic,cveverycv4cvhourscvascvneededcvforcvpaincvincvacvmotorcvvehiclecvac
cv cv
cidentcvvictim.cvThecvnursecviscvawarecvthiscvdrugcvhascvacvhighcvabusecvpotenti
al.cvUndercvwhatcvcategorycvwouldcvmorphinecvbecvclassified?
A) SchedulecvI
B) SchedulecvII
C) SchedulecvIII
D) SchedulecvIV
Ans: B
Feedback:
NarcoticscvwithcvacvhighcvabusecvpotentialcvarecvclassifiedcvascvSchedulecvIIcv
drugscvbecausecvofcvseverecvdependencecvliability.cvSchedulecvIcvdrugscvhavec
vhighcvabusecvpotentialcvandcvnocvacceptedcvmedicalcvuse.cvSchedulecvIIIcvdru
gscvhavecvacvlessercvabusecvpotentialcvthancvIIcvandcvancvacceptedcvmedicalcvus
e.cvSchedulecvIVcvdrugscvhavecvlowcvabusecvpotentialcvandcvlimitedcvdependen
cecvliability.
3.
WhencvinvolvedcvincvphasecvIIIcvdrugcvevaluationcvstudies,cvwhatcvrespon
sibilitiescvwouldcvthecvnursecvhave?
A) Workingcvwithcvanimalscvwhocvarecvgivencvexperimentalc v drugs
B) Choosingcvappropriatecvpatientscvtocvbecvinvolvedcvincvthecvdrugc v study
C) Monitoringcvandcvobservingcvpatientscvcloselycvforcvadversec v effects
D) Conductingcvresearchcvtocvdeterminecveffectivenesscvofcvthec v drug
Ans: C
Feedback:
, PhasecvIIIcvstudiescvinvolvecvusecvofcvacvdrugcvincvacvvastcvclinicalcvpopulationcv
incvwhichcvpatientscvarecvaskedcvtocvrecordcvanycvsymptomscvtheycvexperiencec
vwhilecvtakingcvthecvdrugs.cvNursescvmaycvbecvresponsiblecvforcvhelpingcvcolle
ctcvandcvanalyzecvthecvinformationcvtocvbecvsharedcvwithcvthecvFoodcvandcvDrugc
vAdministrationcv(FDA)cvbutcvwouldcvnotcvconductcvresearchcvindependentlycv
becausecvnursescvdocvnotcvprescribecvmedications.cvUsecvofcvanimalscvincvdrugc
vtestingcviscvdonecvincvthecvpreclinicalcvtrials.cvSelectcvpatientscvwhocvarecvinvo
lvedcvincvphasecvIIcvstudiescvtocvparticipatecvincvstudiescvwherecvthecvparticipan
tscvhavecvthecvdiseasecvthecvdrugcviscvintendedcvtocvtreat.cvThesecvpatientscvarecv
monitoredcvcloselycvforcvdrugcvactioncvandcvadversecveffects.cvPhasecvIcvstudie
scvinvolvecvhealthycvhumancvvolunteerscvwhocvarecvusuallycvpaidcvforcvtheircvp
articipation.cvNursescvmaycvobservecvforcvadversecveffectscvandcvtoxicity.
4.
Whatcvconceptcviscvconsideredcvwhencvgenericcvdrugscvarecvsubstitutedcv
forcvbrandcvnamecvdrugs?
A) Bioavailability
B) Criticalcvconcentration
C) Distribution
D) Half-life
Ans: A
Feedback:
Bioavailabilitycviscvthecvportioncvofcvacvdosecvofcvacvdrugcvthatcvreachescvthecvs
ystemiccvcirculationcvandcviscvavailablecvtocvactcvoncvbodycvcells.cvBinderscvus
edcvincvacvgenericcvdrugcvmaycvnotcvbecvthecvsamecvascvthosecvusedcvincvthecvbr
andcvnamecvdrug.cvTherefore,cvthecvwaycvthecvbodycvbreakscvdowncvandcvusesc
vthecvdrugcvmaycvdiffer,cvwhichcvmaycveliminatecvacvgenericcvdrugcvsubstitutio
n.cvCriticalcvconcentrationcviscvthecvamountcvofcvacvdrugcvthatcviscvneededcvtocv
causecvacvtherapeuticcveffectcvandcvshouldcvnotcvdiffercvbetweencvgenericcvand
cvbrandcvnamecvmedications.cvDistributioncviscvthecvphasecvofcvpharmacokinet
ics,cvwhichcvinvolvescvthecvmovementcvofcvacvdrugcvtocvthecvbodyscvtissuescva
ndcviscvthecvsamecvincvgenericcvandcvbrandcvnamecvdrugs.cvAcvdrugscvhalf-
lifecviscvthecvtimecvitcvtakescvforcvthecvamountcvofcvdrugcvtocvdecreasecvtocvhalfc
vthecvpeakcvlevel,cvwhichcvshouldcvnotcvchangecvwhencvsubstitutingcvacvgeneri
cc v medication.
